{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:31:28Z","timestamp":1770885088233,"version":"3.50.1"},"reference-count":48,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJUI Compass"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>This systematic meta\u2010analysis aimed to assess the effectiveness of triptorelin therapy in reducing lower urinary tract symptoms (LUTS) in men with prostate cancer (PCa).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Preferred Reporting Items for Systematic Reviews and Meta\u2010Analyses (PRISMA) guidelines were followed. PubMed, Web of Science and EMBASE databases were searched for studies conducted between 2013 and 2023. Eligible studies included PCa patients undergoing androgen deprivation therapy (ADT) with triptorelin, with reported baseline and follow\u2010up International Prostate Symptom Scores (IPSS) and quality of life (QoL) data. The Newcastle\u2013Ottawa Scale (NOS) was used to assess the risk of bias, and a random\u2010effects model was applied for the meta\u2010analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 29 articles were identified, and three studies met the inclusion criteria. Triptorelin therapy showed a clinically significant reduction in IPSS over 48\u2009weeks in PCa patients with moderate to severe LUTS. The meta\u2010analysis revealed a pooled effect size of 1.05 (95% CI: 0.65; 1.45), indicating a statistically significant improvement in LUTS. QoL also improved in patients receiving triptorelin therapy, although heterogeneity among the studies and a moderate to high risk of bias were noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Triptorelin therapy demonstrated a positive impact on LUTS in PCa patients. The meta\u2010analysis showed significant reductions in IPSS scores and improved QoL after 48\u2009weeks of triptorelin treatment. However, the results should be interpreted cautiously due to study heterogeneity and potential biases. Further well\u2010designed studies are needed to confirm these findings and determine the optimal use of triptorelin for managing LUTS in men with PCa.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice<\/jats:title><jats:p>Triptorelin therapy may offer an effective treatment option for men with PCa experiencing moderate to severe LUTS. Its positive impact on QoL can lead to improved patient well\u2010being and treatment adherence. Clinicians should consider triptorelin as a potential treatment choice, especially in patients who may be reluctant to undergo surgical interventions for their LUTS. However, careful patient selection and close monitoring are essential due to the observed study heterogeneity and risk of bias. Future research should focus on evaluating triptorelin's cost\u2010effectiveness and comparing its efficacy with other LH\u2010RH agonists in managing LUTS in PCa patients.<\/jats:p><jats:p>Video Abstract: URL (Reviewers\/Editors to select from) Link 1: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/brighton.cloud.panopto.eu\/Panopto\/Pages\/Viewer.aspx?id%3D071419c8-1ad5-4502-a222-b04300c2ca5e\">https:\/\/brighton.cloud.panopto.eu\/Panopto\/Pages\/Viewer.aspx?id=071419c8-1ad5-4502-a222-b04300c2ca5e<\/jats:ext-link><\/jats:p><jats:p>Link 2: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/brighton.cloud.panopto.eu\/Panopto\/Pages\/Viewer.aspx?id%3Db6305a8a-b977-4fcd-a69e-b04300bed728\">https:\/\/brighton.cloud.panopto.eu\/Panopto\/Pages\/Viewer.aspx?id=b6305a8a-b977-4fcd-a69e-b04300bed728<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1002\/bco2.292","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:44:08Z","timestamp":1697071448000},"page":"17-28","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta\u2010analysis"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0004-2131","authenticated-orcid":false,"given":"Ravina","family":"Barrett","sequence":"first","affiliation":[{"name":"School of Applied Sciences University of Brighton  Brighton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1031-093X","authenticated-orcid":false,"given":"Brian","family":"Birch","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust  Southampton UK"},{"name":"School of Medicine University of Southampton  Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Cancer Research UK.Prostate cancer statistics [Internet].2019[cited 2023 April 12]. Available from:https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer#heading-FiveAccessed Dec 20 2022."},{"key":"e_1_2_11_3_1","unstructured":"NHS Digital.Cancer registration statistics England [internet].2019[cited 2022 Dec 21]. Available from:https:\/\/digital.nhs.uk\/data\u2010and\u2010information\/publications\/statistical\/cancer\u2010registration\u2010statistics\/england\u20102019\/the\u2010rate\u2010of\u2010people\u2010dying\u2010from\u2010cancer\u2010in\u2010england\u2010continues\u2010to\u2010decrease#:~:text=The%20incidence%20rate%20for%20prostate 2010%20to%2046%20in%202019"},{"key":"e_1_2_11_4_1","unstructured":"Excellence NIfHaC.Suspected cancer: recognition and referral [NG12]."},{"key":"e_1_2_11_5_1","unstructured":"England PH.Prostate cancer risk management programme: overview."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3581"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2019.60.4.244"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.2_suppl.30"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1493"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287217712379"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000007"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/2377960818811773"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0444-x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.02.026"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25031"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345423"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12142"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2018.09.001"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5555"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.01.074"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-7125(05)70159-0"},{"issue":"7","key":"e_1_2_11_23_1","first-page":"1","article-title":"Validity of the \u201cbother score\u201d in the evaluation and treatment of symptomatic benign prostatic hyperplasia","volume":"2","author":"O'leary MP","journal-title":"Rev Urol"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000155709.37840.fe"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.475"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/1117-6806.189002"},{"issue":"7","key":"e_1_2_11_27_1","first-page":"451","article-title":"Sensitivity and specificity of international prostate symptom score (IPSS) for the screening of Iranian patients with prostate cancer","volume":"49","author":"Hosseini M","year":"2011","journal-title":"Acta Med Iran"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198096"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.134246"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-1"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4"},{"key":"e_1_2_11_33_1","unstructured":"EndNote T.EndNote X9 2013."},{"key":"e_1_2_11_34_1","unstructured":"WellsGA SheaB O'ConnellD et al.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses. Oxford 2000."},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01381-z"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530495"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_2_11_38_1","unstructured":"SaulB.Compute standardized mean differences package \u2018smd\u2019. [published Online First: 2020\u201010\u201022]."},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215574480"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.22037\/uj.v0i0.4245"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12114"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-018-0337-4"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/978194"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/rru.s125791"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18171"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11121-015-0610-7"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.101"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_65_21"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14168"}],"container-title":["BJUI Compass"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bco2.292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T18:17:45Z","timestamp":1759947465000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1002\/bco2.292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/bco2.292"],"URL":"https:\/\/doi.org\/10.1002\/bco2.292","archive":["Portico"],"relation":{},"ISSN":["2688-4526","2688-4526"],"issn-type":[{"value":"2688-4526","type":"print"},{"value":"2688-4526","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"2023-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}